BIOVIT Stock Overview
Operates as a medical technology company in Sweden and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Bio Vitos Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.48 |
| 52 Week High | SEK 6.95 |
| 52 Week Low | SEK 0.23 |
| Beta | 1.78 |
| 1 Month Change | -39.52% |
| 3 Month Change | -65.79% |
| 1 Year Change | -83.31% |
| 3 Year Change | -97.43% |
| 5 Year Change | -98.44% |
| Change since IPO | -99.21% |
Recent News & Updates
Shareholder Returns
| BIOVIT | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | 59.7% | 0.4% | -2.7% |
| 1Y | -83.3% | -8.1% | 4.6% |
Return vs Industry: BIOVIT underperformed the Swedish Medical Equipment industry which returned -8.1% over the past year.
Return vs Market: BIOVIT underperformed the Swedish Market which returned 4.6% over the past year.
Price Volatility
| BIOVIT volatility | |
|---|---|
| BIOVIT Average Weekly Movement | 28.6% |
| Medical Equipment Industry Average Movement | 6.9% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.3% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: BIOVIT's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: BIOVIT's weekly volatility (29%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 1 | Jesper Birgemo | biovitospharma.com |
Bio Vitos Pharma AB (publ) operates as a medical technology company in Sweden and internationally. The company develops and commercializes Helge, which detects hemolysis in vacuum tubes and blood gas samples. It serves emergency departments in the European Union and the United States.
Bio Vitos Pharma AB (publ) Fundamentals Summary
| BIOVIT fundamental statistics | |
|---|---|
| Market cap | SEK 18.87m |
| Earnings (TTM) | -SEK 14.46m |
| Revenue (TTM) | SEK 1.01m |
18.6x
P/S Ratio-1.3x
P/E RatioIs BIOVIT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOVIT income statement (TTM) | |
|---|---|
| Revenue | SEK 1.01m |
| Cost of Revenue | SEK 712.42k |
| Gross Profit | SEK 301.30k |
| Other Expenses | SEK 14.76m |
| Earnings | -SEK 14.46m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.37 |
| Gross Margin | 29.72% |
| Net Profit Margin | -1,426.37% |
| Debt/Equity Ratio | 0% |
How did BIOVIT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 10:08 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bio Vitos Pharma AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|